Neeraj Agarwal

Also affiliated with Huntsman Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

10.1158/1535-7163.22523659

Top 100%

0DataRank

Top 100%0 citations

Nicolas Sayegh, Yeonjung Jo, Benjamin Haaland, Taylor Ryan McFarland, Roberto Nussenzveig +7 more

Papers

Driven by 56 papers — median percentile 0. Top paper: “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The Lancet(2020)10.1016/s0140-6736(20)31187-9

N/A

11.9DataRank · unranked

1804 citations

Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera +95 more

A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0024

N/A

1.7DataRank · unranked

59 citations

Stephanie Daignault‐Newton, Scott A. Tomlins, Neeraj Agarwal, Przemyslaw Twardowski, Alicia K. Morgans +11 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2591

N/A

1.2DataRank · unranked

26 citations

Roberto Nussenzveig, Andrew W. Hahn, John M. Hoffman, Kathryn A. Morton, Sumati Gupta +10 more

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Journal of Clinical Oncology(2024)10.1200/jco.23.01544

N/A

0.930DataRank · unranked

19 citations

Se Eun Kim, Wayne Harris, Sumanta K. Pal, Michael R. Pins, Jill Kolesar +13 more

Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform

The Oncologist(2021)10.1002/onco.13869

N/A

0.745DataRank · unranked

16 citations

Andrew W. Hahn, Roberto Nussenzveig, Sergiusz Wesołowski, Nicolas Sayegh, Benjamin L. Maughan +11 more

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z

N/A

0.742DataRank · unranked

140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology(2025)10.1200/jco-25-01608

N/A

0.674DataRank · unranked

20 citations

Matthew D. Galsky, Nazlı Dizman, David H. Aggen, Neeraj Agarwal, Hikmat Al‐Ahmadie +39 more

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

European Urology(2020)10.1016/j.eururo.2020.06.033

N/A

0.657DataRank · unranked

79 citations

Pedro Isaacsson Velho, Roberto Nussenzveig, Jonathan Chipman, Víctor Sacristán Santos, Stephanie Erickson +9 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0.553DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3587

N/A

0.533DataRank · unranked

34 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +16 more

Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

British Journal of Urology(2021)10.1111/bju.15324

N/A

0.505DataRank · unranked

28 citations

Ali Raza Khaki, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +41 more

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.06.001

N/A

0.505DataRank · unranked

28 citations

Rafee Talukder, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +47 more

Pan-Cancer Interrogation of B7-H3 ( CD276 ) as an Actionable Therapeutic Target Across Human Malignancies

Cancer Research Communications(2024)10.1158/2767-9764.crc-23-0546

N/A

0.500DataRank · unranked

27 citations

John R. Lozada, Nicholas A. Zorko, Andrew Elliott, Allison Makovec, Milan Radovich +18 more

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102018

N/A

0.494DataRank · unranked

26 citations

Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazlı Dizman +23 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0.457DataRank · unranked

8 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.11.014

N/A

0.442DataRank · unranked

18 citations

Fadi Taza, Navonil De Sarkar, Alok K. Tewari, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz +32 more

SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps402

N/A

0.434DataRank · unranked

17 citations

Catherine M. Tangen, Abhishek Tripathi, Brian Shuch, Sumanta K. Pal, Pedro C. Barata +9 more

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European Urology(2023)10.1016/j.eururo.2023.03.036

N/A

0.360DataRank · unranked

10 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +11 more

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2022)10.1016/j.clgc.2022.08.006

N/A

0.345DataRank · unranked

9 citations

Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas Nikolaos Diamantopoulos, Scott J. Dawsey, Shilpa Gupta +49 more

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

European Urology Oncology(2024)10.1016/j.euo.2024.03.001

N/A

0.345DataRank · unranked

9 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo +17 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0.330DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5001

N/A

0.312DataRank · unranked

7 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara +15 more

Association of prior local therapy and outcomes with programmed‐death ligand‐1 inhibitors in advanced urothelial cancer

British Journal of Urology(2021)10.1111/bju.15603

N/A

0.283DataRank · unranked

5 citations

Rafee Talukder, Leonidas Nikolaos Diamantopoulos, Lucía Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky +42 more

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial

BMC Cancer(2024)10.1186/s12885-024-12260-3

N/A

0.278DataRank · unranked

4 citations

Lea Haverbeck Simon, Kelsey E. Maslana, Sarah Taylor, Kish Larson, Pamela A. Hansen +9 more

Co-deletion of ATAD1 with PTEN primes cells for BIM-mediated apoptosis

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.07.01.450781

N/A

0.269DataRank · unranked

5 citations

Heidi L. Fresenius, Heather R. Keys, Corey N. Cunningham, Jeremy Ryan, Deepika Sirohi +9 more

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00813-3

N/A

0.241DataRank · unranked

4 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5506

N/A

0.241DataRank · unranked

4 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +14 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0.208DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5074

N/A

0.165DataRank · unranked

2 citations

Catherine M. Tangen, Maha Hussain, Shilpa Gupta, Yeonjung Jo, Andrea Harzstark +15 more

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

European Urology Oncology(2024)10.1016/j.euo.2024.10.013

N/A

0.165DataRank · unranked

2 citations

Yeonjung Jo, Arshit Narang, Melissa Plets, Chadi Hage Chehade, Georges Gebrael +10 more

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5071

N/A

0.165DataRank · unranked

2 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5080

N/A

0.165DataRank · unranked

2 citations

Catherine M. Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek Pinski +13 more

Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy

European Urology Oncology(2024)10.1016/j.euo.2024.04.013

N/A

0.104DataRank · unranked

1 citations

Nicolas Sayegh, Beverly Chigarira, Georges Gebrael, Nishita Tripathi, Roberto Nussenzveig +10 more

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5048

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +10 more

Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.6532

N/A

0DataRank · unranked

0 citations

Umang Swami, Yeonjung Jo, Georges Gebrael, Benjamin Haaland, Shilpa Gupta +7 more

Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States

Cancers(2021)10.3390/cancers13194951

N/A

0DataRank · unranked

51 citations

Jennifer A. Sinnott, Benjamin Haaland, Nicolas Sayegh, Taylor Ryan McFarland, Nishita Tripathi +8 more

Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial

UNC Libraries(2020)10.17615/wr8m-5r63

N/A

0DataRank · unranked

0 citations

Lisa M. Pappas, Harry R. Hill, David A. Lipschitz, Yoshio Nakamura, Thomas B. Martins +8 more

Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong

UNC Libraries(2020)10.17615/apsd-vp34

N/A

0DataRank · unranked

0 citations

Jerry D. Gardner, Paul C. LaStayo, Lisa M. Pappas, Sierra Smith, Neeraj Agarwal +5 more

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5523

N/A

0DataRank · unranked

0 citations

Edward Mayerson, Erik Gertz, Catherine M. Tangen, Amir Goldkorn, Marta Van Loan +9 more

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.106

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Catherine M. Tangen, Neeraj Agarwal, Heather H. Cheng, Nicholas J. Vogelzang +5 more

Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations

Kidney Cancer(2024)10.3233/kca-240016

N/A

0DataRank · unranked

4 citations

Georges Gebrael, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Gliceida Galarza Fortuna +11 more

Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer(2024)10.1016/j.clgc.2024.102287

N/A

0DataRank · unranked

1 citations

Yeonjung Jo, Georges Gebrael, Nishita Tripathi, Beverly Chigarira, Ayana Srivastava +9 more

Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer

JCO Precision Oncology(2020)10.1200/po.19.00284

N/A

0DataRank · unranked

13 citations

Andrew W. Hahn, Ashley L. Kapron, Wendy Kohlmann, Samantha Greenberg, Timothy J. Parnell +7 more

First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma

Journal of Kidney Cancer and VHL(2025)10.15586/jkcvhl.v12i2.387

N/A

0DataRank · unranked

3 citations

Yeonjung Jo, Georges Gebrael, Chadi Hage Chehade, Zeynep İrem Özay, Blake Nordblad +11 more

The Influence of the Germline HSD3B1 Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate Cancer

Cancers(2025)10.3390/cancers17081270

N/A

0DataRank · unranked

1 citations

Allison Makovec, Carly D. Miller, Shayan Nazari, Andrew Elliott, Aiden Deacon +10 more

Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction

eLife(2022)10.7554/elife.82860

N/A

0DataRank · unranked

20 citations

Heidi L. Fresenius, Corey N. Cunningham, Peng Wei, Heather R. Keys, Jordan A. Berg +12 more

Supplementary Figure from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

10.1158/1535-7163.22523659

Top 100%

0DataRank

Top 100%0 citations

Nicolas Sayegh, Yeonjung Jo, Benjamin Haaland, Taylor Ryan McFarland, Roberto Nussenzveig +7 more

ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma

Oncogene(2022)10.1038/s41388-022-02460-1

N/A

0DataRank · unranked

62 citations

Maria Carolina Ferreira, Daniel G. Fuja, Ethan C. Reichert, Alexandre Rosa Campos, Sophie J. Cowman +9 more

ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.06.01.494206

N/A

0DataRank · unranked

3 citations

Maria Carolina Ferreira, Daniel G. Fuja, Ethan C. Reichert, Alexandre Rosa Campos, Sophie J. Cowman +8 more

Impact of pretest video genetic education in prostate cancer patients: Do patients need us?

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.068

N/A

0DataRank · unranked

1 citations

Elizabeth Woelmer, Morgan Devlin, Sara Low, Amanda Anson, Wendy Kohlmann +12 more

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.02.010

N/A

0DataRank · unranked

58 citations

Michael T. Schweizer, Kim N., Rahul Aggarwal, Neeraj Agarwal, James L. Gulley +9 more

Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4542

N/A

0DataRank · unranked

0 citations

Víctor Sacristán Santos, Roberto Nussenzveig, Sergiusz Wesołowski, Edgar J. Hernández, Alexander Ryan Henrie +6 more

Body composition and metastatic prostate cancer survivorship

Cancer Treatment and Research Communications(2021)10.1016/j.ctarc.2021.100322

N/A

0DataRank · unranked

11 citations

Nicolas Sayegh, Neeraj Agarwal, Adriana M. Coletta

A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree

Cancers(2021)10.3390/cancers13102399

N/A

0DataRank · unranked

5 citations

Craig C. Teerlink, Jeff Stevens, Franklin W. Huang, Csilla Sipeky, Johanna Schleutker +5 more

High-Risk Pedigree Study Identifies LRBA (rs62346982) as a Likely Predisposition Variant for Prostate Cancer

Cancers(2023)10.3390/cancers15072085

N/A

0DataRank · unranked

3 citations

Jeff Stevens, Julio C. Facelli, Craig C. Teerlink, Kristina Allen-Brady, Neeraj Agarwal +1 more

Neeraj Agarwal

Indexed papers

Top data-sharing exemplar

Papers